Journal Article

FZJ-2013-02822

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-18F-Fluorethyl)-L-tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging.

Galldiks, N. (Corresponding author)FZJ* ; Rapp, M. ; Stoffels, G.FZJ* ; Dunkl, V.FZJ* ; Sabel, M. ; Langen, K.-J.FZJ*

2013
Decker Hamilton, Ont.

This record in other databases:    

Please use a persistent id in citations: doi:10.2310/7290.2013.00051

Abstract: AbstractAntiangiogenic treatment using bevacizumab in brain tumor patients may cause difficulties in the diagnosis of tumor progression (ie, nonenhancing tumor progression). Newly defined criteria for treatment assessment and diagnosis of tumor progression (ie, RANO [Response Assessment in Neuro-Oncology] criteria) have implemented signal alterations on T2/fluid-attenuated inversion recovery (FLAIR) sequences to changes in contrast enhancement. However, T2/FLAIR hyperintensity may be influenced by other causes (eg, radiation-induced leukoencephalopathy, peritumoral edema, gliosis). Positron emission tomography using the radiolabeled amino acid O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET-PET) may help detect the metabolically active tumor extent. We present 18F-FET-PET imaging findings in a glioblastoma patient during bevacizumab treatment suggesting an earlier diagnosis of tumor progression than magnetic resonance imaging changes, which are based on the RANO criteria.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)
2. Physik der Medizinischen Bildgebung (INM-4)

Research Program(s):

1. 332 - Imaging the Living Brain (POF2-332) (POF2-332)

Appears in the scientific report 2013

---

Database coverage:
; Current Contents - Clinical Medicine ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---